Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03332576 · ClinicalTrials.gov registry record · Phase 1
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
A Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT03332576 is a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 37 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03332576, a Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or peritoneal cancer.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- BIOLOGICAL DPX-Survivac
- BIOLOGICAL DPX-Survivac(Aqueous)
Study Locations (3)
New York
- Winthrop University Hospital - Mineola
- Lenox Hill Hospital - New York
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-08-23 |
| Est. Completion | 2019-09-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03332576
The ClinicalTrials.gov registry entry for NCT03332576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The listed sponsor is ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03332576 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Ontario.
Frequently Asked Questions
What is clinical trial NCT03332576 about?
NCT03332576 is a clinical study titled "Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer". As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The combination treatment is being evaluated in a non-randomized, multi-cohort study as post-chemotherapy treatment for pa...
What is the current status of trial NCT03332576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-08-23. Estimated completion is 2019-09-09.
What conditions does trial NCT03332576 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT03332576?
The interventions under investigation include: Cyclophosphamide (DRUG), DPX-Survivac (BIOLOGICAL), DPX-Survivac(Aqueous) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03332576?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03332576 being conducted?
This trial has 3 study locations across New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 1
-
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
A Study of ZN-c3 in Patients With Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.